SARS-CoV-2 Variants of Concern and Their Properties

Abstract

Since its first detection in December 2019, SARS-CoV-2 has resulted in the morbibidity of 174 million and mortality of 3.74 million people. As a typical Ribo nucleic acid virus, SARS-CoV-2 undergoes genomic changes during its replication to maintain its evolutionary adaptation. Continous mutation has led into the emergence of numerous variants. Currently, the strains distinguished as the ‘Variants of Concern’ are the B.1.1.7 lineage (The United Kingdom variant) , B.1.351 (The South African variant), B.1.1.248/B1.1.28/P1(Brazilian Variant) , B.1.427/B.1.429 lineage (The Californian variant) and B.1.617.2 lineage (Indian variant). These variants impose a huge concern due to their properties of higher transmission and evasion of the immune system. The continuous emergence of such variants can be contained by vaccinating the population to reduce the circulation of the virus and by maintaining the major protective measures against the disease.

Keywords

• SARS-CoV-2
• Variants of Concern
• Mutations
• Immune system

SARS-CoV-2 Endişe Verici Varyantları ve Özellikleri

Abstract

Aralık 2019'da tespit edilmesinden bu yana, SARS-CoV-2, 174 milyon insanın morbiditesine ve 3.74 milyon insanın mortalitesine neden olmuştur. Tipik bir Ribo nükleik asit virüsü olarak, SARS-CoV-2, evrimsel adaptasyonunu korumak için replikasyon sırasında genomik değişikliklere uğrar. Zaman içindeki sürekli mutasyonlar, çok sayıda varyantın ortaya çıkmasına neden olmuştur. Şu anda, ‘Endişe Verici Varyantları’ olarak ayırt edilen varyantlar B. 1.1.7 soyu (Birleşik Krallık varyantı), B. 1.351 (Güney Afrika varyantı), B. 1.1.248/B1.1.28/P1 (Brezilya varyantı), B. 1.427/B.1.429 soyu (Kaliforniya varyantı) ve B. 1.617.2 soyu (Hint varyantı) içermektedir. Bu Varyantlar, yüksek bulaşma özellikleri ve bağışıklık sisteminden kaçma yetenekleri nedeniyle büyük bir endişe yaratmaktadır. Bu tür varyantların sürekli ortaya çıkışı, virüsün dolaşımını azaltmak için popülasyonun aşılanması ve hastalığa karşı ana koruyucu önlemlerin sürdürülmesi ile kontrol edilebilir.

Keywords

• SARS-CoV-2
• Endişe verici Varyantlar
• Mutasyonlar
• Bağışıklık sistem

References

1. Singhal T. A Review of Coronavirus Disease-2019 (COVID-19). Indian J Pediatr. 2020;87(4):281–286.
2. WHO. WHO Timeline - COVID-19. Available from: https://www.who.int/news-room/detail/27-04-2020-who-timeline---covid-19
3. Covid-19 Coronavirus pandemic. [cited 2020 Aug 8]. Available from: https://www.worldometers.info/coronavirus/
4. Hasöksüz M, Kiliç S, Saraç F. Coronaviruses and sars-cov-2. Turkish J Med Sci. 2020;50(SI-1):549–556.
5. Harapan H, Itoh N, Yufika A, Winardi W, Keam S, Te H, et al. Review article on Coronavirus. J Infect Public Health. 2020;13(5):667–673.
6. Anand KB, Karade S, Sen S, Gupta RM. SARS-CoV-2: Camazotz’s Curse. Med J Armed Forces India. 2020;76(2):136–141. doi: 10.1016/j.mjafi.2020.04.008
7. Alm E, Broberg EK, Connor T, Hodcroft EB, Komissarov AB, Maurer-Stroh S, et al. Geographical and temporal distribution of SARS-CoV-2 clades in the WHO European Region, January to June 2020. Eurosurveillance. 2020;25(32):1–8. doi: 10.2807/1560-7917.ES.2020.25.32.2001410
8. CDC centers for DC and P. SARS-CoV-2 Variant classifications and definitions. 2021. Available from: https://www.cdc.gov/coronavirus/2019-ncov/variants/variant-info.html#

9. Control EC for DP and. SARS-CoV-2 variants of concern as of 24 May 2022. Available from: https://www.ecdc.europa.eu/en/covid-19/variants-concern
10. Napoli. MCMRAASCDR Di. Features, evaluation, and treatment of coronavirus (COVID-19). STAT PEARLS Publishing; 2021. Available from: https://www.ncbi.nlm.nih.gov/books/NBK554776/
11. Janik E, Niemcewicz M, Podogrocki M, Majsterek I, Bijak M. The emerging concern and ,nterest SARS-CoV-2 variants. Patholgy. 2021; 10(6):1–13.
12. Korber B, Wm F, Gnanakaran S, Yoon H, Theiler J, Abfalterer W, et al. Spike mutation pipeline reveals the emergence of a more transmissible form of SARS-CoV-2 Introduction. bioRxiv. 2020;1–33. doi: 10.1101/2020.04.29.069054
13. Mercatelli D, Giorgi FM. Geographic and genomic distribution of SARS-CoV-2 mutations. Front Microbiol. 2020;11(July):1–13.
14. Toyoshima Y, Nemoto K, Matsumoto S, Nakamura Y, Kiyotani K. SARS-CoV-2 genomic variations associated with mortality rate of COVID-19. J Hum Genet. 2020;65(12):1075–1082. doi: 10.1038/s10038-020-0808-9
15. WHO. SARS-CoV-2 Variant – United Kingdom of Great Britain and Northern Ireland. 2020. Available from: https://www.who.int/csr/don/21-december-2020-sars-cov2-variant-united-kingdom/en/
16. COG-UK update on SARS-CoV-2 Spike mutations of special interest Report 1. 2020;01:1–9.
17. Luan B, Wang H, Huynh T. Molecular Mechanism of the N501Y Mutation for Enhanced Binding between SARS-CoV-2's Spike Protein and Human ACE2 Receptor. bioRxiv. 2021;2021.01.04.425316. Available from: http://biorxiv.org/content/early/2021/01/05/2021.01.04.425316.abstract
18. COG-UK report on SARS-CoV-2 Spike mutations of interest in the UK. 2021;1:1–41.
19. Singh J. Structure-function investigation of a new VUI-202012 / 01 SARS-CoV-2 variant. bioRxiv. 2021;1–8. doi: 10.1101/2021.01.01.42502
20. GISAID. Pandemic coronavirus causing COVID-19. 2021 2021 Feb 6. Available from: https://www.epicov.org/epi3/frontend#5b9109
21. England PH. Variants: distribution of cases data, 20 May 2021. Available from: https://www.gov.uk/government/publications/covid-19-variants-genomically-confirmed-case-numbers/variants-distribution-of-cases-data#definition
22. Genç K. COVID-19 in Turkey: a nation on edge. Lancet [Internet]. 2021;397(10287):1794–6. doi: 10.1016/S0140-6736(21)01098-9
23. Tegally H, Wilkinson E, Giovanetti M, Iranzadeh A, Fonseca V, Giandhari J, et al. Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa. Arghavan Alisoltani-Dehkordi. 2020;10:2020.12.21.20248640. doi: 10.1101/2020.12.21.20248640
24. Wang P, Nair MS, Liu L, Iketani S, Luo Y, Guo Y, et al. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. Nature. 2021;593(7857):130–135.
25. Piccoli L, Park YJ, Tortorici MA, Czudnochowski N, Walls AC, Beltramello M, et al. Mapping Neutralizing and immunodominant sites on the SARS-CoV-2 spike receptor-binding domain by structure-guided high-resolution serology. Cell. 2020;183(4):1024-1042.e21.
26. Becker M, Dulovic A, Junker D, Ruetalo N, Kaiser PD, Pinilla YT, et al. Immune response to SARS-CoV-2 variants of concern in vaccinated individuals. Nat Commun [Internet]. 2021;12(1):1–8. doi: 10.1038/s41467-021-23473-6
27. Candido S, Mishra S, Crispim MAE, Sales FC, Jesus JG De, Andrade PS, et al. Genomics and epidemiology of a novel SARS-CoV-2 lineage in Manaus, Brazil. medRxiv. 2021;1–45. doi: 10.1101/2021.02.26.21252554
28. Cantón R, De Lucas Ramos P, García-Botella A, García-Lledó A, Gómez-Pavón J, González Del Castillo J, et al. New variants of SARS-CoV-2. Rev Esp Quimioter. 2021;1–10. Available from: http://www.ncbi.nlm.nih.gov/pubmed/34076402
29. Long SW, Olsen RJ, Christensen PA, Subedi S, Olson R, Davis JJ, et al. Sequence analysis of 20,453 severe acute respiratory syndrome coronavirus 2 genomes from the houston metropolitan area ıdentifies the emergence and widespread distribution of multiple ısolates of all major variants of concern. Am J Pathol. 2021; doi: 10.1016/j.ajpath.2021.03.004
30. Xianding Deng, Miguel A Garcia-Knight, Mir M. Khalid VS, Candace Wang, Mary Kate Morris, Alicia Sotomayor-González DR. et al. Transmission, infectivity, and antibody neutralization of an emerging SARS-CoV_2 variant in California carrying a L452R spike protein mutation. medRxiv. 2021;1–47. doi: 10.1101/2021.03.07.21252647
31. Matthew Mc., Jessica B, Anna M, Alex C, Alexandra C.W, Julia D. et al. SARS-CoV-2 immune evasion by variant B.1.427/B.1.429. bioRxiv. 2021; doi: 10.1101/2021.03.31.437925
32. Singh J, Rahman SA, Ehtesham NZ, Hira S, Hasnain SE. SARS-CoV-2 variants of concern are emerging in India. Nat Med. 2021; 1126–1134
33. Centre E. Emergence of SARS-CoV-2 B . 1 . 617 variants in India and situation in the EU / EEA Event background epidemiology. 2021;(May):1–12.
34. Vaidyanathan G. Coronavirus variants are spreading in India — what scientists know so far. 2021; Available from: https://www.nature.com/articles/d41586-021-01274-7.